Enabling Therapies develops innovative therapeutics based on proprietary platform technologies with high diversification potential that enable therapies for diseases with currently dissatisfying treatment options.
ethris – Enabling Therapies
Ethris develops innovative therapeutics based on proprietary platform technologies with high diversification potential that enable therapies for diseases with currently dissatisfying treatment options.
Ethris appoints Brad Guild, former Head of Emerging technologies at Pfizer, as Head of International Operations
Ethris GmbH, a pioneer in the emerging field of messenger RNA (mRNA) medicine, announces the appointment of Brad Guild as Head of International Operations. Mr Guild brings to Ethris more than 27 years of experience in developing nucleic acid therapies, gene therapies and antibodies, most recently as Head of Emerging Technology at Pfizer Worldwide in Cambridge, Mass.
Since March 23, 2015, Ethris operates in a brand new building in Planegg. The new facility offers 1,500 square meters of lab and office space. Moving there has offered the opportunity to design the laboratories and offices specifically according to the needs of Ethris’ growing work force in R&D and administration.
Ethris explores the code of life for enabling patients’ bodies to make their own protein drugs. The proprietary SNIM®RNA platform and tailor-made delivery systems for systemic, local, oral and aerosol administration reduce gene therapy without genes to practice of medical need. SNIM®RNA “Transcript Therapies” are unprecedented treatment options for numerous diseases.